Cover Image
市場調查報告書

幼年型特異性關節炎(史迪爾氏症):開發平台分析

Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 303578
出版日期 內容資訊 英文 88 Pages
訂單完成後即時交付
價格
Back to Top
幼年型特異性關節炎(史迪爾氏症):開發平台分析 Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H2 2015
出版日期: 2015年10月30日 內容資訊: 英文 88 Pages
簡介

史迪爾氏症是發炎的疾病,特徵為間歇性的高燒、粉紅色皮疹的出現或消失、關節痛等。史迪爾氏症是青年性類風濕性關節炎(JRA)的一種,亦稱之為幼年型特異性關節炎。主要的症狀有食慾不振、噁心、體重減少等。此外淋巴腺朣大、脾臟及肝臟肥大化、喉嚨痛等症狀也很常見。主要的治療法有抗發炎劑(非甾體抗炎藥物(NSAID)和類固醇劑)等。

本報告提供全球各國治療幼年型特異性關節炎(史迪爾氏症)所用之開發中產品的開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,彙整主要企業簡介,主要藥物概要,最新的產業趨勢等調查結果。

目錄

簡介

  • 分析範圍

幼年型特異性關節炎(史迪爾氏症)概要

治療藥的開發

  • 突發性幼年型關節炎開發中產品:概要
  • 突發性幼年型關節炎開發中產品:比較分析

各企業開發中的突發性幼年型關節炎治療藥

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品
  • 不明確的階段的產品

突發性幼年型關節炎治療藥:開發中的產品一覽(各企業)

突發性幼年型關節炎開發治療藥的企業

  • Biocon Limited
  • Epirus Biopharmaceuticals, Inc.
  • Genor BioPharma Co., Ltd.
  • Hetero Drugs Limited
  • Mabion SA
  • Mycenax Biotech Inc.
  • Oncobiologics, Inc.
  • Oncodesign SA
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Sandoz International GmbH
  • Swedish Orphan Biovitrum AB
  • Therapeutic Proteins International, LLC
  • UCB S.A.

突發性幼年型關節炎:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • adalimumab的生技仿製藥
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • anakinra (基因重組)
  • certolizumab pegol
  • DNX-514
  • etanercept的生技仿製藥
  • 克隆氏症(發炎性腸道疾病) RIP2 抑制劑
  • tocilizumab的生技仿製藥
  • tofacitinib

突發性幼年型關節炎治療藥:開發中產品的最新趨勢

突發性幼年型關節炎治療藥:暫停中的計劃

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7258IDB

Summary

Global Markets Direct's, 1'Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H2 2015', provides an overview of the Idiopathic Juvenile Arthritis (Still's Disease)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Idiopathic Juvenile Arthritis (Still's Disease)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Idiopathic Juvenile Arthritis (Still's Disease) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Idiopathic Juvenile Arthritis (Still's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Idiopathic Juvenile Arthritis (Still's Disease) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Idiopathic Juvenile Arthritis (Still's Disease)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Idiopathic Juvenile Arthritis (Still's Disease) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Idiopathic Juvenile Arthritis (Still's Disease) Overview
  • Therapeutics Development
    • Pipeline Products for Idiopathic Juvenile Arthritis (Still's Disease) - Overview
    • Pipeline Products for Idiopathic Juvenile Arthritis (Still's Disease) - Comparative Analysis
  • Idiopathic Juvenile Arthritis (Still's Disease) - Therapeutics under Development by Companies
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Idiopathic Juvenile Arthritis (Still's Disease) - Products under Development by Companies
  • Idiopathic Juvenile Arthritis (Still's Disease) - Companies Involved in Therapeutics Development
    • Biocon Limited
    • Epirus Biopharmaceuticals, Inc.
    • Genor BioPharma Co., Ltd.
    • Hetero Drugs Limited
    • Mabion SA
    • Mycenax Biotech Inc.
    • Oncobiologics, Inc.
    • Oncodesign SA
    • Panacea Biotec Limited
    • Pfizer Inc.
    • Sandoz International GmbH
    • Swedish Orphan Biovitrum AB
    • Therapeutic Proteins International, LLC
    • UCB S.A.
  • Idiopathic Juvenile Arthritis (Still's Disease) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • anakinra (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • certolizumab pegol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DNX-514 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit RIP2 for Crohn's Disease and Polyarthritis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tocilizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tocilizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tocilizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tofacitinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Idiopathic Juvenile Arthritis (Still's Disease) - Recent Pipeline Updates
  • Idiopathic Juvenile Arthritis (Still's Disease) - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Idiopathic Juvenile Arthritis (Still's Disease), H2 2015
  • Number of Products under Development for Idiopathic Juvenile Arthritis (Still's Disease) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Biocon Limited, H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Genor BioPharma Co., Ltd., H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Hetero Drugs Limited, H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Mabion SA, H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Mycenax Biotech Inc., H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Oncobiologics, Inc., H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Oncodesign SA, H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Panacea Biotec Limited, H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Pfizer Inc., H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Sandoz International GmbH, H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Swedish Orphan Biovitrum AB, H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by Therapeutic Proteins International, LLC, H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline by UCB S.A., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) Therapeutics - Recent Pipeline Updates, H2 2015
  • Idiopathic Juvenile Arthritis (Still's Disease) - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Idiopathic Juvenile Arthritis (Still's Disease), H2 2015
  • Number of Products under Development for Idiopathic Juvenile Arthritis (Still's Disease) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top